Yurong Lai

All Stories

1. 
   Drug-Drug Interaction Assessments of Clinical Transporter Inhibition: Learnings from the Transporter Working Group from the International Consortium for Innovation and Quality in Pharmaceutical Development

   Article • Drug Metabolism and Disposition, February 2026, Elsevier

   Yurong Lai

2. 
   Mechanism-guided Untargeted-to-targeted Lipidomics Identifies Phosphatidylcholine 38:4 in Rat Bile as an Abcb4/Mdr2 Inhibition Marker

   Article • Drug Metabolism and Disposition, February 2026, Elsevier

   Yurong Lai

3. 
   Bridging in vitro and clinical data: Experimental insights into the IC50 variability of dolutegravir as an organic cation transporter 2 inhibitor

   Article • Drug Metabolism and Disposition, June 2025, Elsevier

   Yurong Lai

4. 
   Identification and Clinical Evaluation of Potential Biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2)

   Article • Clinical Pharmacology & Therapeutics, April 2025, Wiley

   Yurong Lai

5. 
   Development and validation of a sensitive method to quantify a poorly ionized drug, pocapavir, in C57BL/6 mouse plasma

   Article • Bioanalysis, March 2025, Taylor & Francis

   Yurong Lai

6. 
   Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers

   Article • Clinical Pharmacology & Therapeutics, November 2024, Wiley

   Yurong Lai

7. 
   50th Anniversary Celebration Collection Special Section on New and Emerging Areas and Technologies in Drug Metabolism and Disposition, Part II—Editorial

   Article • Drug Metabolism and Disposition, November 2024, Elsevier

   Yurong Lai

8. 
   Scientific Contributions to Drug Metabolism by Dr. Edward T. Morgan, the Recipient of the Bernard B. Brodie Award in Drug Metabolism and Disposition in 2024–Editorial

   Article • Drug Metabolism and Disposition, October 2024, Elsevier

   Yurong Lai

9. 
   Special Section on Mechanisms of Drug Metabolism in Acetaminophen-Induced Hepatotoxicity—Editorial

   Article • Drug Metabolism and Disposition, August 2024, Elsevier

   Yurong Lai

10. 
    Survey of Pharmaceutical Industry’s Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Work...

    Article • Drug Metabolism and Disposition, July 2024, Elsevier

    Yurong Lai

11. 
    Special Section on Cytochrome P450 Enzymes in Toxicology and as Drug Targets—Editorial

    Article • Drug Metabolism and Disposition, June 2024, Elsevier

    Yurong Lai

12. 
    CYP7A1 Gene Induction via SHP-Dependent or Independent Mechanisms can Increase the Risk of Drug-Induced Liver Injury Independently or in Synergy with BSEP Inhibition

    Article • Drug Metabolism and Disposition, May 2024, Elsevier

    Yurong Lai

13. 
    Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs

    Article • Drug Metabolism and Disposition, March 2024, Elsevier

    Yurong Lai

14. 
    Membrane transporters in drug development and as determinants of precision medicine

    Article • Nature Reviews Drug Discovery, January 2024, Springer Science + Business Media

    Yurong Lai

15. 
    Building a Predictive PBPK Model for Human OATP Substrates: a Strategic Framework for Early Evaluation of Clinical Pharmacokinetic Variations Using Pitavastatin as an Example

    Article • The AAPS Journal, January 2024, Springer Science + Business Media

    Yurong Lai

16. 
    Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model

    Article • CPT Pharmacometrics & Systems Pharmacology, October 2023, Wiley

    Yurong Lai

17. 
    Interpretation of Protein-Mediated Uptake of Statins by Hepatocytes Is Confounded by the Residual Statin-Protein Complex

    Article • Drug Metabolism and Disposition, October 2023, Elsevier

    Yurong Lai

18. 
    Special Section on New and Emerging Areas and Technologies in Drug Metabolism and Disposition, Part I–Editorial

    Article • Drug Metabolism and Disposition, October 2023, Elsevier

    Yurong Lai

19. 
    Special Section on Mechanism-Based Predictive Methods in Drug Discovery and Development—Editorial

    Article • Drug Metabolism and Disposition, September 2023, Elsevier

    Yurong Lai

20. 
    The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition–Progress from 2016 to 2023

    Article • Drug Metabolism and Disposition, August 2023, Elsevier

    Yurong Lai

21. 
    Characterization of Elimination Pathways and the Feasibility of Endogenous Metabolites as Biomarkers of Organic Anion Transporter 1/3 Inhibition in Cynomolgus Monkeys

    Article • Drug Metabolism and Disposition, July 2023, Elsevier

    Yurong Lai

22. 
    Editorial: Clinical trials in drug metabolism and transport: 2022

    Article • Frontiers in Pharmacology, June 2023, Frontiers

    Yurong Lai

23. 
    Special Section on Perspectives on Drug Metabolism and Disposition, Part I—Editorial

    Article • Drug Metabolism and Disposition, June 2023, Elsevier

    Yurong Lai

24. 
    Special Section on Drug Metabolism and Precision Medicine—Editorial

    Article • Drug Metabolism and Disposition, March 2023, Elsevier

    Yurong Lai

25. 
    Special Section on Xenobiotic Receptors–Editorial

    Article • Drug Metabolism and Disposition, February 2023, Elsevier

    Yurong Lai

26. 
    Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes

    Article • CPT Pharmacometrics & Systems Pharmacology, December 2022, Wiley

    Yurong Lai

27. 
    Editorial: Emerging talents in Frontiers in Pharmacology: Drug metabolism and transport 2022

    Article • Frontiers in Pharmacology, December 2022, Frontiers

    Yurong Lai

28. 
    Human and nonclinical disposition of [14C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection

    Article • Xenobiotica, November 2022, Taylor & Francis

    Yurong Lai

29. 
    Special Section on Mechanistic and Translational Research on Transporters in Toxicology–Editorial

    Article • Drug Metabolism and Disposition, October 2022, Elsevier

    Yurong Lai

30. 
    The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans

    Article • Pharmacology & Therapeutics, October 2022, Elsevier

    Yurong Lai

31. 
    Development and validation of an LC–MS/MS method to quantify kynurenic acid in human plasma

    Article • Bioanalysis, October 2022, Taylor & Francis

    Yurong Lai

32. 
    Special Section on New Era of Transporter Science: Unraveling the Functional Role of Orphan Transporters–Editorial

    Article • Drug Metabolism and Disposition, September 2022, Elsevier

    Yurong Lai

33. 
    Special Section on Drug Metabolism and Regulation—Editorial

    Article • Drug Metabolism and Disposition, July 2022, Elsevier

    Yurong Lai

34. 
    Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4

    Article • Clinical Pharmacology & Therapeutics, June 2022, Wiley

    Yurong Lai

35. 
    Special Section on Pharmacokinetics and ADME of Biological Therapeutics–Editorial

    Article • Drug Metabolism and Disposition, June 2022, Elsevier

    Yurong Lai

36. 
    Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development

    Article • Acta Pharmaceutica Sinica B, June 2022, Elsevier

    Yurong Lai

37. 
    Clinical relevance of hepatic and renal P‐gp/ BCRP inhibition of drugs: An International Transporter Consortium perspective

    Article • Clinical Pharmacology & Therapeutics, May 2022, Wiley

    Yurong Lai

38. 
    Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs

    Article • Clinical and Translational Science, May 2022, Wiley

    Yurong Lai

39. 
    Special Section On Drug Metabolism in Liver Injury and Repair—Editorial

    Article • Drug Metabolism and Disposition, May 2022, Elsevier

    Yurong Lai

40. 
    Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions

    Article • Clinical Pharmacology & Therapeutics, April 2022, Wiley

    Yurong Lai

41. 
    Special Section on Bile Acids, Drug Metabolism, and Toxicity—Editorial

    Article • Drug Metabolism and Disposition, April 2022, Elsevier

    Yurong Lai

42. 
    Kidney transporters drug discovery, development, and safety

    Article • Current Opinion in Toxicology, March 2022, Elsevier

    Yurong Lai

43. 
    Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition

    Article • Drug Metabolism and Disposition, December 2021, Elsevier

    Yurong Lai

44. 
    Correction to “Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs”

    Article • Journal of Medicinal Chemistry, October 2021, American Chemical Society (ACS)

    Yurong Lai

45. 
    Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance

    Article • Expert Opinion on Drug Metabolism & Toxicology, June 2021, Taylor & Francis

    Yurong Lai

46. 
    Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys

    Article • Clinical and Translational Science, May 2021, Wiley

    Yurong Lai

47. 
    Intestinal Excretion, Intestinal Recirculation, and Renal Tubule Reabsorption Are Underappreciated Mechanisms That Drive the Distribution and Pharmacokinetic Behavior of Small Molecule Drugs

    Article • Journal of Medicinal Chemistry, May 2021, American Chemical Society (ACS)

    Yurong Lai

48. 
    Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach

    Article • Drug Metabolism and Disposition, February 2021, Elsevier

    Yurong Lai

49. 
    Transporter Gene Regulation in Sandwich Cultured Human Hepatocytes Through the Activation of Constitutive Androstane Receptor (CAR) or Aryl Hydrocarbon Receptor (AhR)

    Article • Frontiers in Pharmacology, January 2021, Frontiers

    Yurong Lai

50. 
    In Vitro Hepatic Uptake in Human and Monkey Hepatocytes in the Presence and Absence of Serum Protein and Its In Vitro to In Vivo Extrapolation

    Article • Drug Metabolism and Disposition, December 2020, Elsevier

    Yurong Lai

51. 
    Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition

    Article • Drug Metabolism and Disposition, August 2020, Elsevier

    Yurong Lai

52. 
    Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications

    Article • Clinical Pharmacology & Therapeutics, July 2020, Wiley

    Yurong Lai

53. 
    Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?

    Article • Drug Metabolism and Disposition, December 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

54. 
    Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo

    Article • Drug Metabolism and Disposition, October 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

55. 
    Toward a Consensus on Applying Quantitative Liquid Chromatography‐Tandem Mass Spectrometry Proteomics in Translational Pharmacology Research: A White Paper

    Article • Clinical Pharmacology & Therapeutics, July 2019, Wiley

    Yurong Lai

56. 
    Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A

    Article • Clinical Pharmacology & Therapeutics, July 2019, Wiley

    Yurong Lai

57. 
    Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells

    Article • Frontiers in Pharmacology, July 2019, Frontiers

    Yurong Lai

58. 
    Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule–Related Therapeutic Modalities

    Article • Drug Metabolism and Disposition, July 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

59. 
    Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug–Drug Interaction and Associated Biomarker Levels in Healthy Volunteers

    Article • Clinical and Translational Science, April 2019, Wiley

    Yurong Lai

60. 
    Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood–Brain Barrier Measured by Quantitative Targeted Proteomics

    Article • Clinical Pharmacology & Therapeutics, March 2019, Wiley

    Yurong Lai

61. 
    A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation

    Article • Drug Metabolism and Disposition, January 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Jashvant Unadkat, Yurong Lai

62. 
    Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

    Article • Clinical Pharmacology & Therapeutics, October 2018, Wiley

    Yurong Lai

63. 
    Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective

    Article • Clinical Pharmacology & Therapeutics, October 2018, Wiley

    Yurong Lai

64. 
    In Vitro Stimulation of Multidrug Resistance-Associated Protein 2 Function Is Not Reproduced In Vivo in Rats

    Article • Pharmaceutics, August 2018, MDPI AG

    Yurong Lai

65. 
    Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition

    Article • Drug Metabolism and Disposition, May 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

66. 
    UHPLC–MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions

    Article • Bioanalysis, May 2018, Future Science

    Yurong Lai

67. 
    Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study

    Article • Drug Metabolism and Disposition, April 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

68. 
    Transporter special issue in DMD

    Article • Drug Metabolism and Disposition, April 2018, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

69. 
    Comparative untargeted proteomic analysis of ADME proteins and tumor antigens for tumor cell lines

    Article • Acta Pharmaceutica Sinica B, March 2018, Elsevier

    Yurong Lai

70. 
    Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation

    Article • Clinical Pharmacology & Therapeutics, January 2018, Wiley

    Yurong Lai

71. 
    Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys

    Article • Drug Metabolism and Disposition, November 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

72. 
    Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics

    Article • Drug Metabolism and Disposition, November 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

73. 
    Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys

    Article • The AAPS Journal, October 2017, Springer Science + Business Media

    Yurong Lai

74. 
    Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone

    Article • Journal of Pharmacology and Experimental Therapeutics, June 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

75. 
    Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects

    Article • Drug Metabolism and Disposition, June 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

76. 
    Molecular properties associated with transporter-mediated drug disposition

    Article • Advanced Drug Delivery Reviews, May 2017, Elsevier

    Manthena Varma, Yurong Lai

77. 
    Coproporphyrin-I: A Fluorescent, Endogenous Optimal Probe Substrate for ABCC2 (MRP2) Suitable for Vesicle-Based MRP2 Inhibition Assay

    Article • Drug Metabolism and Disposition, March 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

78. 
    Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1

    Article • Journal of Pharmacology and Experimental Therapeutics, January 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

79. 
    Organic Anion Transporter 2: An Enigmatic Human Solute Carrier

    Article • Drug Metabolism and Disposition, November 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

80. 
    Disrupted Murine Gut–to–Human Liver Signaling Alters Bile Acid Homeostasis in Humanized Mouse Liver Models

    Article • Journal of Pharmacology and Experimental Therapeutics, October 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

81. 
    Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics

    Article • Drug Metabolism and Disposition, August 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

82. 
    Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment

    Article • Biopharmaceutics & Drug Disposition, July 2016, Wiley

    Yurong Lai

83. 
    Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition

    Article • Journal of Pharmacology and Experimental Therapeutics, June 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

84. 
    Disruption of BSEP Function in HepaRG Cells Alters Bile Acid Disposition and Is a Susceptive Factor to Drug-Induced Cholestatic Injury

    Article • Molecular Pharmaceutics, March 2016, American Chemical Society (ACS)

    Yurong Lai

85. 
    Involvement of Drug Transporters in Organ Toxicity: The Fundamental Basis of Drug Discovery and Development

    Article • Chemical Research in Toxicology, March 2016, American Chemical Society (ACS)

    Yurong Lai

86. 
    Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species

    Article • Journal of Pharmacology and Experimental Therapeutics, February 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

87. 
    Mechanistic Modeling of Pitavastatin Disposition in Sandwich-Cultured Human Hepatocytes: A Proteomics-Informed Bottom-Up Approach

    Article • Drug Metabolism and Disposition, February 2016, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

88. 
    Diclofenac and Its Acyl Glucuronide: Determination of In Vivo Exposure in Human Subjects and Characterization as Human Drug Transporter Substrates In Vitro

    Article • Drug Metabolism and Disposition, December 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

89. 
    Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation

    Article • Drug Metabolism and Disposition, November 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

90. 
    Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide

    Article • Molecular Pharmaceutics, November 2015, American Chemical Society (ACS)

    Manthena Varma, Yurong Lai

91. 
    Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake

    Article • Drug Metabolism and Disposition, September 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

92. 
    Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression

    Article • Drug Metabolism and Disposition, April 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

93. 
    Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys

    Article • Journal of Pharmacology and Experimental Therapeutics, March 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

94. 
    Protein Abundance of Clinically Relevant Multidrug Transporters along the Entire Length of the Human Intestine

    Article • Molecular Pharmaceutics, September 2014, American Chemical Society (ACS)

    Yurong Lai

95. 
    Transporters in Drug Discovery

    Article • August 2014, Wiley

    Manthena Varma, Yurong Lai

96. 
    Permeability Comparison between Hepatocyte and Low Efflux MDCKII Cell Monolayer

    Article • The AAPS Journal, May 2014, Springer Science + Business Media

    Yurong Lai

97. 
    Quantitative Targeted Proteomics for Membrane Transporter Proteins: Method and Application

    Article • The AAPS Journal, May 2014, Springer Science + Business Media

    Yurong Lai

98. 
    Hepatic Uptake of Atorvastatin: Influence of Variability in Transporter Expression on Uptake Clearance and Drug-Drug Interactions

    Article • Drug Metabolism and Disposition, May 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Yurong Lai

99. 
    Beyond the ITC White Paper: Emerging Sciences in Drug Transporters and Opportunities for Drug Development

    Article • Current Pharmaceutical Design, March 2014, Bentham Science Publishers

    Yurong Lai

100. 
     Inhibition of Hepatobiliary Transporters by A Novel Kinase Inhibitor Contributes to Hepatotoxicity in Beagle Dogs

     Article • Drug Metabolism Letters, December 2013, Bentham Science Publishers

     Yurong Lai

101. 
     LC–MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins

     Article • Journal of Pharmaceutical and Biomedical Analysis, November 2013, Elsevier

     Yurong Lai

102. 
     Drug-Induced Perturbations of the Bile Acid Pool, Cholestasis, and Hepatotoxicity: Mechanistic Considerations beyond the Direct Inhibition of the Bile Salt Export Pump

     Article • Drug Metabolism and Disposition, October 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

103. 
     Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin

     Article • Biopharmaceutics & Drug Disposition, October 2013, Wiley

     Manthena Varma, Yurong Lai

104. 
     A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development

     Article • Drug Metabolism and Disposition, September 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

105. 
     Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes

     Article • Journal of Pharmaceutical Sciences, September 2013, Elsevier

     Yurong Lai

106. 
     In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development

     Article • Clinical Pharmacology & Therapeutics, April 2013, Springer Science + Business Media

     Yurong Lai, Bruno Stieger

107. 
     Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

     Article • Clinical Pharmacology & Therapeutics, April 2013, Springer Science + Business Media

     Yurong Lai

108. 
     Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”

     Article • Pharmaceutical Research, March 2013, Springer Science + Business Media

     Manthena Varma, Yurong Lai

109. 
     Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP/ABCG2): Effect of Age, Sex, and Genotype

     Article • Journal of Pharmaceutical Sciences, March 2013, Elsevier

     Yurong Lai

110. 
     Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma

     Article • Hepatology, February 2013, Wiley

     Yurong Lai

111. 
     Quantitative Prediction of Repaglinide-Rifampicin Complex Drug Interactions Using Dynamic and Static Mechanistic Models: Delineating Differential CYP3A4 Induction and OATP1B1 Inhibition Potential of Rifampicin

     Article • Drug Metabolism and Disposition, February 2013, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

112. 
     Model-based approaches to predict drug–drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond

     Article • Expert Opinion on Drug Metabolism & Toxicology, January 2013, Informa Healthcare

     Manthena Varma, Yurong Lai

113. 
     Mechanistic Modeling to Predict the Transporter- and Enzyme-Mediated Drug-Drug Interactions of Repaglinide

     Article • Pharmaceutical Research, January 2013, Springer Science + Business Media

     Manthena Varma, Yurong Lai

114. 
     About the author

     Article • January 2013, Elsevier

     Yurong Lai

115. 
     Applications of Targeted Proteomics in ADME for IVIVE

     Article • January 2013, Springer Science + Business Media

     Yurong Lai

116. 
     Breast cancer resistance protein (BCRP)/ABCG2

     Article • January 2013, Elsevier

     Yurong Lai

117. 
     Drug transporters in drug discovery and development

     Article • January 2013, Elsevier

     Yurong Lai

118. 
     Membrane Protein Quantification by Peptide-Based Mass Spectrometry Approaches: Studies on the Organic Anion-Transporting Polypeptide Family

     Article • Journal of Proteomics & Bioinformatics, January 2013, OMICS Publishing Group

     Yurong Lai

119. 
     Multidrug resistance-associated protein 2 (MRP2/ABCC2)

     Article • January 2013, Elsevier

     Yurong Lai

120. 
     Organic anion, organic cation and zwitterion transporters of the SLC22 and SLC47 superfamily (OATs, OCTs, OCTNs and MATEs)

     Article • January 2013, Elsevier

     Yurong Lai

121. 
     Organic anion-transporting polypeptides (OATPs/SLCOs)

     Article • January 2013, Elsevier

     Yurong Lai

122. 
     P-glycoprotein (P-gp/MDR1)/ABCB1

     Article • January 2013, Elsevier

     Yurong Lai

123. 
     The bile salt export pump (BSEP/ABCB11)

     Article • January 2013, Elsevier

     Yurong Lai

124. 
     Transporter study methodologies

     Article • January 2013, Elsevier

     Yurong Lai

125. 
     Characterization of Organic Anion Transporting Polypeptide (OATP) Expression and Its Functional Contribution to the Uptake of Substrates in Human Hepatocytes

     Article • Molecular Pharmaceutics, November 2012, American Chemical Society (ACS)

     Yurong Lai

126. 
     Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design

     Article • European Journal of Medicinal Chemistry, November 2012, Elsevier

     Yurong Lai

127. 
     Solute Carrier (SLC) Family Transporters

     Article • October 2012, Wiley

     Yurong Lai

128. 
     A Novel Relay Method for Determining Low-Clearance Values

     Article • Drug Metabolism and Disposition, May 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

129. 
     Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

     Article • Pharmaceutical Research, May 2012, Springer Science + Business Media

     Manthena Varma, Yurong Lai

130. 
     Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions

     Article • Journal of Medicinal Chemistry, May 2012, American Chemical Society (ACS)

     Yurong Lai

131. 
     Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion

     Article • Drug Metabolism and Disposition, May 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

132. 
     Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development

     Article • Expert Opinion on Drug Metabolism & Toxicology, April 2012, Informa Healthcare

     Manthena Varma, Yurong Lai

133. 
     In Vitro Evaluation of Hepatic Transporter-Mediated Clinical Drug-Drug Interactions: Hepatocyte Model Optimization and Retrospective Investigation

     Article • Drug Metabolism and Disposition, March 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

134. 
     Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data

     Article • Drug Metabolism and Disposition, February 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

135. 
     Interindividual Variability in Hepatic Expression of the Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2): Quantification by Liquid Chromatography/Tandem Mass Spectrometry

     Article • Drug Metabolism and Disposition, February 2012, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

136. 
     Quantitative Membrane Proteomics and its Application in Translational Pharmacology

     Article • Journal of Proteomics & Bioinformatics, January 2012, OMICS Publishing Group

     Yurong Lai

137. 
     The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance

     Article • Xenobiotica, November 2011, Taylor & Francis

     Yurong Lai

138. 
     Development of a new permeability assay using low‐efflux MDCKII cells

     Article • Journal of Pharmaceutical Sciences, November 2011, Elsevier

     Manthena Varma, Yurong Lai

139. 
     Differential Modulation of Cytochrome P450 Activity and the Effect of 1-Aminobenzotriazole on Hepatic Transport in Sandwich-Cultured Human Hepatocytes

     Article • Drug Metabolism and Disposition, October 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

140. 
     Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples

     Article • Rapid Communications in Mass Spectrometry, May 2011, Wiley

     Yurong Lai

141. 
     Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution

     Article • Bioorganic & Medicinal Chemistry Letters, May 2011, Elsevier

     Yurong Lai

142. 
     Pharmacokinetic Interaction of the Antiparasitic Agents Ivermectin and Spinosad in Dogs

     Article • Drug Metabolism and Disposition, February 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

143. 
     Two Branched Polar Groups and Polar Linker Moieties of Thiophene Amide Derivatives Are Essential for MRP2/ABCC2 Recognition

     Article • Drug Metabolism Letters, December 2010, Bentham Science Publishers

     Yurong Lai

144. 
     ADME

     Article • November 2010, Wiley

     Yurong Lai

145. 
     Regulation of MRP2/ABCC2 and BSEP/ABCB11 Expression in Sandwich Cultured Human and Rat Hepatocytes Exposed to Inflammatory Cytokines TNF-α, IL-6, and IL-1β

     Article • Journal of Biological Chemistry, August 2010, American Society for Biochemistry & Molecular Biology (ASBMB)

     Yurong Lai

146. 
     Novel Metabolic Bioactivation Mechanism for a Series of Anti-Inflammatory Agents (2,5-Diaminothiophene Derivatives) Mediated by Cytochrome P450 Enzymes

     Article • Drug Metabolism and Disposition, June 2010, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

147. 
     Preclinical and Clinical Evidence for the Collaborative Transport and Renal Secretion of an Oxazolidinone Antibiotic by Organic Anion Transporter 3 (OAT3/SLC22A8) and Multidrug and Toxin Extrusion Protein 1 (MATE1/SLC47A1)

     Article • Journal of Pharmacology and Experimental Therapeutics, June 2010, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

148. 
     Improved Extrapolation of Hepatobiliary Clearance fromin VitroSandwich Cultured Rat Hepatocytes through Absolute Quantification of Hepatobiliary Transporters

     Article • Molecular Pharmaceutics, May 2010, American Chemical Society (ACS)

     Yurong Lai

149. 
     Evaluation of Drug Transporter Interactions in Drug Discovery and Development

     Article • Combinatorial Chemistry & High Throughput Screening, February 2010, Bentham Science Publishers

     Yurong Lai

150. 
     Pharmacokinetic and Pharmacodynamic Evaluation of the Suitability of Using Fluticasone and an Acute Rat Lung Inflammation Model to Differentiate Lung Versus Systemic Efficacy

     Article • Journal of Pharmaceutical Sciences, November 2009, Elsevier

     Yurong Lai

151. 
     Identification of interspecies difference in hepatobiliary transporters to improve extrapolation of human biliary secretion

     Article • Expert Opinion on Drug Metabolism & Toxicology, July 2009, Informa Healthcare

     Yurong Lai

152. 
     Quantitative Expression Profile of Hepatobiliary Transporters in Sandwich Cultured Rat and Human Hepatocytes

     Article • Molecular Pharmaceutics, July 2009, American Chemical Society (ACS)

     Yurong Lai

153. 
     Advancement of Structure-Activity Relationship of Multidrug Resistance-Associated Protein 2 Interactions

     Article • The AAPS Journal, June 2009, Springer Science + Business Media

     Yurong Lai

154. 
     Evaluation of in Vitro Models for Screening Alkaline Phosphatase-Mediated Bioconversion of Phosphate Ester Prodrugs

     Article • Drug Metabolism and Disposition, April 2009, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

155. 
     LC−MS/MS Mediated Absolute Quantification and Comparison of Bile Salt Export Pump and Breast Cancer Resistance Protein in Livers and Hepatocytes across Species

     Article • Analytical Chemistry, March 2009, American Chemical Society (ACS)

     Yurong Lai

156. 
     Saturation of Multidrug-Resistant Protein 2 (Mrp2/Abcc2)-Mediated Hepatobiliary Secretion: Nonlinear Pharmacokinetics of a Heterocyclic Compound in Rats after Intravenous Bolus Administration

     Article • Drug Metabolism and Disposition, January 2009, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

157. 
     Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery

     Article • Nanoscale Research Letters, January 2009, Springer Science + Business Media

     Yurong Lai

158. 
     Absolute Difference of Hepatobiliary Transporter Multidrug Resistance-Associated Protein (MRP2/Mrp2) in Liver Tissues and Isolated Hepatocytes from Rat, Dog, Monkey, and Human

     Article • Drug Metabolism and Disposition, October 2008, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

159. 
     Comparison of In vitro Nanoparticles Uptake in Various Cell Lines and In vivo Pulmonary Cellular Transport in Intratracheally Dosed Rat Model

     Article • Nanoscale Research Letters, September 2008, Springer Science + Business Media

     Yurong Lai

160. 
     Absolute quantification of multidrug resistance-associated protein 2 (MRP2/ABCC2) using liquid chromatography tandem mass spectrometry

     Article • Analytical Biochemistry, September 2008, Elsevier

     Yurong Lai

161. 
     Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human

     Article • European Journal of Pharmaceutical Sciences, September 2008, Elsevier

     Yurong Lai

162. 
     In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta

     Article • AJP Regulatory Integrative and Comparative Physiology, November 2007, American Physiological Society

     Yurong Lai

163. 
     Enhanced production of p24 Gag protein in HIV-1-infected rat cells fused with uninfected human cells

     Article • Experimental and Molecular Pathology, August 2007, Elsevier

     Yurong Lai

164. 
     Structure-Activity Relationships for Interaction with Multidrug Resistance Protein 2 (ABCC2/MRP2): The Role of Torsion Angle for a Series of Biphenyl-Substituted Heterocycles

     Article • Drug Metabolism and Disposition, March 2007, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

165. 
     Identification of the Mitochondrial Targeting Signal of the Human Equilibrative Nucleoside Transporter 1 (hENT1)

     Article • Journal of Biological Chemistry, April 2006, American Society for Biochemistry & Molecular Biology (ASBMB)

     Yurong Lai

166. 
     Changes in Pharmacokinetics of Anti-HIV Protease Inhibitors during Pregnancy: The Role of CYP3A and P-glycoprotein

     Article • Journal of Pharmacology and Experimental Therapeutics, November 2005, American Society for Pharmacology & Experimental Therapeutics (ASPET)

     Yurong Lai

167. 
     Conserved residues F316 and G476 in the concentrative nucleoside transporter 1 (hCNT1) affect guanosine sensitivity and membrane expression, respectively

     Article • AJP Cell Physiology, January 2005, American Physiological Society

     Yurong Lai

168. 
     Improving branch prediction accuracy with parallel conservative correctors

     Article • January 2005, ACM (Association for Computing Machinery)

     Yurong Lai

169. 
     Mitochondrial Expression of the Human Equilibrative Nucleoside Transporter 1 (hENT1) Results in Enhanced Mitochondrial Toxicity of Antiviral Drugs

     Article • Journal of Biological Chemistry, November 2003, American Society for Biochemistry & Molecular Biology (ASBMB)

     Yurong Lai

170. 
     Epstein-barr virus infection of rat lymphocytes expressing human CD21 results in restricted latent viral gene expression and not in immunoblastic transformation

     Article • Journal of Medical Virology, March 2003, Wiley

     Yurong Lai

171. 
     Simultaneous Expression of hCNT1-CFP and hENT1-YFP in Madin-Darby Canine Kidney Cells

     Article • Journal of Biological Chemistry, July 2002, American Society for Biochemistry & Molecular Biology (ASBMB)

     Yurong Lai

172. 
     A Single Glycine Mutation in the Equilibrative Nucleoside Transporter Gene, hENT1, Alters Nucleoside Transport Activity and Sensitivity to Nitrobenzylthioinosine†

     Article • Biochemistry, February 2002, American Chemical Society (ACS)

     Yurong Lai

173. 
     Iron depletion prevents adenine nucleotide decomposition and an increase of xanthine oxidase activity in the liver of the Long Evans Cinnamon (LEC) rat, an animal model of Wilson's disease

     Article • Life Sciences, August 1999, Elsevier

     Yurong Lai

174. 
     The Effect of Subcutaneous Tetrathiomolybdate Administration on Copper and Iron Metabolism, Including their Regional Redistribution in the Brain, in the Long-Evans Cinnamon Rat, abona fideAnimal Model for Wilson's Disease

     Article • Pharmacology & Toxicology, May 1999, Wiley

     Yurong Lai

175. 
     Decreased hepatobiliary secretion of inorganic mercury, its deposition and toxicity in the Eisai hyperbilirubinemic rat with no hepatic canalicular organic anion transporter

     Article • Toxicology, February 1998, Elsevier

     Yurong Lai

176. 
     Outputs of hepatic copper and cadmium stimulated by tetrathiomolybdate (TTM) injection in Long-Evans Cinnamon (LEC) rats pretreated with cadmium, and in Fischer rats pretreated with copper and cadmium

     Article • Toxicology, June 1997, Elsevier

     Yurong Lai

177. 
     Lack of biliary excretion of Cd linked to an inherent defect of the canalicular isoform of multidrug resistance protein (cMrp) does not abnormally stimulate accumulation of Cd in the Eisai hyperbilirubinemic (EHB) rat liver

     Article • Archives of Toxicology, April 1997, Springer Science + Business Media

     Yurong Lai

178. 
     Biliary excretion of copper, manganese, and horseradish peroxidase in eisai hyperbilirubinemic mutant rats (EHBRs) with defective biliary excretion of glutathione

     Article • Biological Trace Element Research, October 1996, Springer Science + Business Media

     Yurong Lai

179. 
     Biliary excretion of exogenous cadmium, and endogenous copper and zinc in the Eisai hyperbilirubinuric (EHB) rat with a near absence of biliary glutathione

     Article • Toxicology, August 1996, Elsevier

     Yurong Lai

180. 
     Accumulation of orally given cadmium in Long-Evans Cinnamon (LEC) rats with an inherently abnormal copper metabolism

     Article • Toxicology, April 1996, Elsevier

     Yurong Lai

181. 
     The protective role of zinc in the toxic action of coal dust upon mouse macrophages.

     Article • Occupational and Environmental Medicine, December 1991, BMJ

     Yurong Lai

182. 
     Influence of rheumatoid factor in coalminers' pneumoconiosis in the Fujian Shaowu colliery, south China.

     Article • Occupational and Environmental Medicine, February 1990, BMJ

     Yurong Lai